Adverse Renal, Endocrine, Hepatic, and Metabolic Events during Maintenance Mood Stabilizer Treatment for Bipolar Disorder: A Population-Based Cohort Study
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
BACKGROUND: There is limited, poorly characterized information about adverse events occurring during maintenance treatment of bipolar disorder. We aimed to determine adverse event rates during treatment with lithium, valproate, olanzapine, and quetiapine. METHODS AND FINDINGS: We conducted a propensity score adjusted cohort study using nationally representative United Kingdom electronic health records from January 1, 1995, until December 31, 2013. We included patients who had a diagnosis of bipolar disorder and were prescribed lithium (n = 2148), valproate (n = 1670), olanzapine (n = 1477), or quetiapine (n = 1376) as maintenance mood stabilizer treatment. Adverse outcomes were chronic kidney disease, thyroid disease, hypercalcemia, weight gain, hypertension, type 2 diabetes mellitus, cardiovascular disease, and hepatotoxicity. The propensity score included important demographic, physical health, and mental health predictors of drug treatment allocation. The median duration of drug treatment was 1.48 y (interquartile range 0.64-3.43). Compared to patients prescribed lithium, those taking valproate, olanzapine, and quetiapine had reduced rates of chronic kidney disease stage 3 or more severe, following adjustment for propensity score, age, and calendar year, and accounting for clustering by primary care practice (valproate hazard ratio [HR] 0.56; 95% confidence interval [CI] 0.45-0.69; p < 0.001, olanzapine HR 0.57; 95% CI 0.45-0.71; p < 0.001, quetiapine HR 0.62; 95% CI 0.47-0.80; p < 0.001). Hypothyroidism was reduced in those taking valproate (HR 0.60; 95% CI 0.40-0.89; p = 0.012) and olanzapine (HR 0.48; 95% CI 0.29-0.77; p = 0.003), compared to those taking lithium. Rates of new onset hyperthyroidism (valproate HR 0.24; 95% CI 0.09-0.61; p = 0.003, olanzapine HR 0.31; 95% CI 0.13-0.73; p = 0.007) and hypercalcemia (valproate HR 0.25; 95% CI 0.10-0.60; p = 0.002, olanzapine HR 0.32; 95% CI 0.14-0.76; p = 0.008, quetiapine HR 0.23; 95% CI 0.07-0.73; p = 0.013) were also reduced relative to lithium. However, rates of greater than 15% weight gain on valproate, olanzapine, and quetiapine were higher (valproate HR 1.62; 95% CI 1.31-2.01; p < 0.001, olanzapine HR 1.84; 95% CI 1.47-2.30; p < 0.001, quetiapine HR 1.67; 95% CI 1.24-2.20; p < 0.001) than in individuals prescribed lithium, as were rates of hypertension in the olanzapine treated group (HR 1.41, 95% CI 1.06-1.87; p = 0.017). We found no significant difference in rates of chronic kidney disease stage 4 or more severe, type 2 diabetes mellitus, cardiovascular disease, or hepatotoxicity. Despite estimates being robust following sensitivity analyses, limitations include the potential for residual confounding and ascertainment bias and an inability to examine dosage effects. CONCLUSIONS: Lithium use is associated with more renal and endocrine adverse events but less weight gain than commonly used alternative mood stabilizers. Risks need to be offset with the effectiveness and anti-suicidal benefits of lithium and the potential metabolic side effects of alternative treatment options.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Austin, P. C. (2011) · Multivariate Behavioral Research · doi:10.1080/00273171.2011.568786 · Cited by 12,242
Whiteford, H. A., Degenhardt, L., Rehm, J., Baxter, A. J., Ferrari, A. J., Erskine, H. E., Charlson, F. J., Norman, R. E., Flaxman, A. D., Johns, N., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61611-6 · Cited by 6,006
Matching Methods for Causal Inference: A Review and a Look Forward
Stuart, E. A. (2010) · Statistical Science · doi:10.1214/09-sts313 · Cited by 5,478 · cited 1×
“In this way, use of a PS aims to replicate a randomized experiment as closely as possible by obtaining treatment groups with similar covariate distributions [48].”
MethodPartial residuals for the proportional hazards regression model
SCHOENFELD, D. (1982) · Biometrika · doi:10.1093/biomet/69.1.239 · Cited by 3,111
Reducing Bias in Observational Studies Using Subclassification on the Propensity Score
Rosenbaum, P. R., & Rubin, D. B. (1984) · Journal of the American Statistical Association · doi:10.1080/01621459.1984.10478078 · Cited by 3,082
Grande, I., Berk, M., Birmaher, B., & Vieta, E. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00241-x · Cited by 1,710
Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis
Cipriani, A., Hawton, K., Stockton, S., & Geddes, J. R. (2013) · BMJ · doi:10.1136/bmj.f3646 · Cited by 920 · cited 1×
“These risks need to be offset with the potentially superior effectiveness and anti-suicidal benefits of the drug compared to other treatment options [5,68].”
BackgroundSelf-citationBlak, B., Thompson, M., Dattani, H., & Bourke, A. (2011) · Journal of Innovation in Health Informatics · doi:10.14236/jhi.v19i4.820 · Cited by 630
The Read clinical classification.
Chisholm, J. (1990) · BMJ · doi:10.1136/bmj.300.6732.1092 · Cited by 504
Miura, T., Noma, H., Furukawa, T. A., Mitsuyasu, H., Tanaka, S., Stockton, S., Salanti, G., Motomura, K., Shimano-Katsuki, S., Leucht, S., et al. (2014) · The Lancet Psychiatry · doi:10.1016/s2215-0366(14)70314-1 · Cited by 364 · cited 2×
“Kingdom National Institute for Health and Care Excellence (NICE) guidelines [3], a metaanalysis [4], and a network meta-analysis [5] all suggested that lithium should be seen as firstline monotherapy, whereas previous guidelines from around the world also recommended valproate, lamotrigine, carbamazepine, olanzapine,…”
BackgroundSelf-citationTesting for chronic kidney disease: a position statement from the National Kidney Foundation
Vassalotti, J. A., Stevens, L. A., & Levey, A. S. (2007) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2007.06.013 · Cited by 331 · cited 1×
“73 m(2)) [34,35] (if eGFR was unavailable we calculated it from available creatinine blood tests using the CKD-EPI equation [36]), hypothyroidism (or a TSH of>10 mU/L), hyperthyroidism (or a TSH<0.”
MethodShine, B., McKnight, R. F., Leaver, L., & Geddes, J. R. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61842-0 · Cited by 313 · cited 2×
“Hypercalcemia is also recognised to be associated with lithium prescribing [11,13,62,63].”
BackgroundSelf-citationMaguire, A., Blak, B. T., & Thompson, M. (2009) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1688 · Cited by 301 · cited 1×
“Patients with a diagnosis of BPD were included if they had at least one 28-day prescription of lithium, valproate, olanzapine, or quetiapine after January 1, 1995 or after the date at which the medical records met quality assurance criteria for data entry (based on computer usage and mortality recording rates [31,32]).”
Lazarus, J. H. (2009) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2009.06.002 · Cited by 230 · cited 1×
“Increased hypothyroidism has been shown previously [11,58], but literature on the association between lithium and hyperthyroidism is inconsistent [13], and lithium-induced hyperthyroidism is considered rare [59].”
BackgroundAccuracy of diagnosis of psychosis on general practice computer system.
Nazareth, I., King, M., Haines, A., Rangel, L., & Myers, S. (1993) · BMJ · doi:10.1136/bmj.307.6895.32 · Cited by 196
Self-citationIdentifying periods of acceptable computer usage in primary care research databases
Horsfall, L., Walters, K., & Petersen, I. (2013) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.3368 · Cited by 148 · cited 1×
“Patients with a diagnosis of BPD were included if they had at least one 28-day prescription of lithium, valproate, olanzapine, or quetiapine after January 1, 1995 or after the date at which the medical records met quality assurance criteria for data entry (based on computer usage and mortality recording rates [31,32]).”
Self-citationThe VAMP research multi-purpose database in the U.K.
Lis, Y. (1995) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(94)00137-f · Cited by 116 · cited 1×
“Approximately 98% of the UK population is registered with a primary care physician [25].”
BackgroundRecording of Severe Mental Illness in United Kingdom Primary Care, 2000–2010
Hardoon, S., Hayes, J. F., Blackburn, R., Petersen, I., Walters, K., Nazareth, I., & Osborn, D. P. J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0082365 · Cited by 90 · cited 1×
“The incidence rate of BPD in THIN has been shown to be similar to European cohorts [26], and the validity of severe mental illness diagnoses held in primary care has been established [27].”
ResultSelf-citationDols, A., Sienaert, P., van Gerven, H., Schouws, S., Stevens, A., Kupka, R., & Stek, M. L. (2013) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e32836435e2 · Cited by 86 · cited 2×
“Valproate has been found to be associated with a high risk of asymptomatic elevated transaminases and can cause idiosyncratic hepatic failure [15,18].”
Background
Cited by
Lithium side effects and toxicity: prevalence and management strategies
Gitlin, M. (2016) · International Journal of Bipolar Disorders · doi:10.1186/s40345-016-0068-y · Cited by 531
Lithium and suicide in mood disorders: Updated meta‐review of the scientific literature
Smith, K. A., & Cipriani, A. (2017) · Bipolar Disorders · doi:10.1111/bdi.12543 · Cited by 247
Tondo, L., Abramowicz, M., Alda, M., Bauer, M., Bocchetta, A., Bolzani, L., Calkin, C. V., Chillotti, C., Hidalgo-Mazzei, D., Manchia, M., et al. (2017) · International Journal of Bipolar Disorders · doi:10.1186/s40345-017-0096-2 · Cited by 125
Fusar-Poli, L., Amerio, A., Cimpoesu, P., Natale, A., Salvi, V., Zappa, G., Serafini, G., Amore, M., Aguglia, E., & Aguglia, A. (2020) · Medicina · doi:10.3390/medicina57010028 · Cited by 28
Lithium Treatment in Children and Adolescents
Duffy, A., & Grof, P. (2018) · Pharmacopsychiatry · doi:10.1055/a-0575-4179 · Cited by 22
“There is also certain disenchantment with neuroleptics as long-term mood stabilizers as the expectation of effectiveness translating from acute to prophylaxis, initially hyped by the industry, has not been achieved, while side effects, including metabolic syndrome, have been more extensively documented [22].”
Background
Metadata
- Authors
- Hayes, J. F., Marston, L., Walters, K., Geddes, J. R., King, M., & Osborn, D. P. J.
- Venue
- PLOS Medicine
- Publisher
- Public Library of Science (PLoS)
- Published
- 2016-08-02
- Volume
- 13
- Issue
- 8
- Pages
- e1002058
- ISSN
- 1549-1277 (ISSN-L)
- 1549-1676
- OpenAlex
- W2481798045
- Cited by
- 115
- References
- 19
- FWCI
- 9.05
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.